Burcon NutraScience Corporation (TSX: BU | OTCQB: BRCNF) has announced results from its Annual General and Special Meeting and revised its commercial guidance for calendar year 2026. Shareholders elected all six director nominees and approved a convertible debenture financing of up to $21 million in aggregate principal proceeds. The company has simultaneously lowered its 2026 revenue outlook, citing production ramp timing, while affirming an expectation of positive cash flow in 2027.

Key Points

  • Burcon NutraScience Corporation (TSX: BU | OTCQB: BRCNF) held its Annual General and Special Meeting on September 24, 2026
  • Shareholders approved a convertible debenture financing of up to $21 million in aggregate principal proceeds, subject to final TSX approval
  • Updated 2026 guidance now targets at least $6 million in revenue and an annualised run rate of at least $10 million exiting the year
  • Investors may be watching for TSX final approval of the financing and progress at the Galesburg production facility

All Six Director Nominees Elected at Burcon's Annual Shareholder Meeting

At the meeting, shareholders elected all six management-nominated directors: Alan Chan, Peter H. Kappel, John A. Vassallo, James Peter Pekar, Philip James Dowad, and Chris Bunio. Five of the six nominees received more than 96% of votes cast in favour, while Peter H. Kappel received approval from 70.44% of votes. Each director will serve until the conclusion of Burcon's next annual general meeting or until a successor is elected or appointed. Shareholders also approved the appointment of KPMG LLP as the company's auditors.

Shareholders Greenlight Up to $21 Million Convertible Debenture Financing

Burcon confirmed that shareholders approved all resolutions related to its previously announced convertible debenture financing, including a disinterested shareholder vote on a specific resolution connected to that transaction. With the required approvals secured, the company announced it intends to proceed with the financing for aggregate principal proceeds of up to $21 million, pending final approval from the Toronto Stock Exchange and satisfaction of remaining closing conditions. A significant portion of the capital is intended to fund production capability, infrastructure, maintenance, and efficiency improvements at the Galesburg production facility.

Burcon Revises 2026 Revenue Outlook, Cites Production Ramp Delays

Burcon updated its commercial guidance, now expecting at least $6 million in revenue for calendar year 2026 and an annualised revenue run rate of at least $10 million exiting the year. The company also expects to achieve positive cash flow in calendar year 2027. The revised outlook reflects the timing of its production ramp and additional equipment and infrastructure investments. CEO Kip Underwood stated that the adjustment reflects production ramp timing and the investments required to reliably support growing demand, adding that the company expects to exit 2026 at a significantly higher revenue run rate.